{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:01:34Z","timestamp":1788307294877,"version":"build-2803163510"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017961","name":"Health Commission of Heilongjiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017961","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["slas-discovery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Discovery"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.slasd.2026.100320","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:11:09Z","timestamp":1781827869000},"page":"100320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["ADCs for colorectal carcinoma: decoding clinical evidence for molecular design innovation"],"prefix":"10.1016","volume":"42","author":[{"given":"Xiangxin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenqi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bomiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxue","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.slasd.2026.100320_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN","author":"Morgan","year":"2023","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.slasd.2026.100320_bib0002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.slasd.2026.100320_bib0003","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/cancers16081530","article-title":"Colorectal Cancer: Epidemiology, Risk Factors, and Prevention","volume":"16","author":"Roshandel","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.slasd.2026.100320_bib0004","first-page":"89","article-title":"Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors","volume":"14","author":"Rawla","year":"2019","journal-title":"Prz Gastroenterol"},{"issue":"10","key":"10.1016\/j.slasd.2026.100320_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101174","article-title":"Global colorectal cancer burden in 2020 and projections to 2040","volume":"14","author":"Xi","year":"2021","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0006","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up \u2606","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0007","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2012drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"issue":"9","key":"10.1016\/j.slasd.2026.100320_bib0009","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.slasd.2026.100320_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14122928","article-title":"Drug Resistance in Colorectal Cancer: From Mechanism to Clinic","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.slasd.2026.100320_bib0011","doi-asserted-by":"crossref","first-page":"11073","DOI":"10.1002\/cam4.5594","article-title":"Novel strategies to reverse chemoresistance in colorectal cancer","volume":"12","author":"Ma","year":"2023","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.slasd.2026.100320_bib0012","first-page":"165","article-title":"Antibody\u2013drug conjugates: Smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"10.1016\/j.slasd.2026.100320_bib0013","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem Soc Rev"},{"issue":"2","key":"10.1016\/j.slasd.2026.100320_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020396","article-title":"Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate","volume":"14","author":"Sheyi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.slasd.2026.100320_bib0015","first-page":"262","article-title":"Reprogramming the tumor microenvironment: synergistic mechanisms of antibody\u2013drug conjugates and immune checkpoint inhibitors","volume":"8","author":"Yin","year":"2025","journal-title":"Antib Ther"},{"issue":"12","key":"10.1016\/j.slasd.2026.100320_bib0016","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"June","key":"10.1016\/j.slasd.2026.100320_bib0017","first-page":"1","article-title":"Immune checkpoint inhibitors in colorectal cancer: limitation and challenges","volume":"15","author":"Yan","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.slasd.2026.100320_bib0018","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4251\/wjgo.v15.i2.240","article-title":"Cold\u201d colorectal cancer faces a bottleneck in immunotherapy","volume":"15","author":"Liu","year":"2023","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"10.1016\/j.slasd.2026.100320_bib0019","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up \u2606","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.slasd.2026.100320_bib0020","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.slasd.2026.100320_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-021-00342-x","article-title":"Tumour heterogeneity and evolutionary dynamics in colorectal cancer","volume":"10","author":"Chan","year":"2021","journal-title":"Oncogenesis"},{"issue":"3","key":"10.1016\/j.slasd.2026.100320_bib0022","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/bjc.2017.171","article-title":"Tumour heterogeneity poses a significant challenge to cancer biomarker research","volume":"117","author":"Cyll","year":"2017","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.slasd.2026.100320_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040806","article-title":"Tumor heterogeneity: A great barrier in the age of cancer immunotherapy","volume":"13","author":"El-Sayes","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.slasd.2026.100320_bib0024","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.slasd.2026.100320_bib0025","first-page":"259","article-title":"Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases","volume":"16","author":"Pan","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.slasd.2026.100320_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/852748","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jncics\/pkad082","article-title":"Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer","volume":"8","author":"Singh","year":"2024","journal-title":"JNCI Cancer Spectr"},{"issue":"12","key":"10.1016\/j.slasd.2026.100320_bib0028","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.slasd.2026.100320_bib0029","first-page":"1","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","author":"Modi","year":"2022","journal-title":"N Engl J Med."},{"issue":"25","key":"10.1016\/j.slasd.2026.100320_bib0030","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.slasd.2026.100320_bib0031","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non\u2013Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0032","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0033","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.slasd.2026.100320_bib0034","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody\u2013drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.slasd.2026.100320_bib0035","first-page":"2022","article-title":"The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target","author":"Faiella","year":"2022","journal-title":"J Oncol"},{"issue":"28","key":"10.1016\/j.slasd.2026.100320_bib0036","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","article-title":"HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence","volume":"40","author":"Fu","year":"2021","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.slasd.2026.100320_bib0037","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.3748\/wjg.v21.i12.3706","article-title":"Prognostic value of c-Met in colorectal cancer: A meta-analysis","volume":"21","author":"Liu","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.slasd.2026.100320_bib0038","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.canlet.2008.02.049","article-title":"c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases","volume":"265","author":"Zeng","year":"2008","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.slasd.2026.100320_bib0039","first-page":"148","article-title":"Targeting MET in cancer therapy","volume":"3","author":"Mo","year":"2017","journal-title":"Chronic Dis Transl Med"},{"issue":"16_suppl","key":"10.1016\/j.slasd.2026.100320_bib0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.3515","article-title":"First-in-human study of ABBV-400, a novel c-Met\u2013targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer","volume":"42","author":"Sharma","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.slasd.2026.100320_bib0041","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.3015","article-title":"Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met\u2013targeting antibody-drug conjugate, in advanced solid tumors","author":"Sharma","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.slasd.2026.100320_bib0042","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/clinchem\/47.4.624","article-title":"Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful?","volume":"47","author":"Duffy","year":"2001","journal-title":"Clin Chem"},{"issue":"24","key":"10.1016\/j.slasd.2026.100320_bib0043","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","article-title":"Preclinical activity of SAR408701: A novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors","volume":"26","author":"Decary","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.slasd.2026.100320_bib0044","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/bjc.2012.605","article-title":"Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting","volume":"108","author":"Tiernan","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-34855-9","article-title":"Clinical implication of tissue carcinoembryonic antigen expression in association with serum carcinoembryonic antigen in colorectal cancer","volume":"13","author":"Aldilaijan","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0046","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/j.annonc.2024.08.642","article-title":"573P M9140, an anti-CEACAM5 antibody drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC): Updated results from a phase I trial","volume":"35","author":"Boni","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.slasd.2026.100320_bib0047","doi-asserted-by":"crossref","unstructured":"Kopetz S, Garcia-Carbonero R, Han SW, et al. Precemtabart tocentecan (Precem-TcT, M9140) in patients with mCRC: Efficacy and safety data at the recommended development dose in the PROCEADE-CRC-01 study. Published online 2026. doi:10.13039\/100009945.","DOI":"10.1200\/JCO.2026.44.2_suppl.129"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0048","doi-asserted-by":"crossref","DOI":"10.4103\/2277-9175.205529","article-title":"EPCAM Expression in Colon Adenocarcinoma and its Relationship with TNM Staging","volume":"6","author":"Mokhtari","year":"2017","journal-title":"Adv Biomed Res"},{"issue":"3","key":"10.1016\/j.slasd.2026.100320_bib0049","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10555-020-09898-3","article-title":"Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?","volume":"39","author":"Gires","year":"2020","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"10.1016\/j.slasd.2026.100320_bib0050","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.bjc.6603505","article-title":"EpCAM an immunotherapeutic target for gastrointestinal malignancy: Current experience and future challenges","volume":"96","author":"Chaudry","year":"2007","journal-title":"Br J Cancer"},{"issue":"19","key":"10.1016\/j.slasd.2026.100320_bib0051","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.slasd.2026.100320_bib0052","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","article-title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"5","key":"10.1016\/j.slasd.2026.100320_bib0053","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000911","article-title":"Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial","volume":"5","author":"Sartore-Bianchi","year":"2020","journal-title":"ESMO open"},{"issue":"11","key":"10.1016\/j.slasd.2026.100320_bib0054","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun (London, England)"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.slasd.2026.100320_bib0056","article-title":"Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation\/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study","volume":"42","author":"Xu","year":"2024","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.slasd.2026.100320_bib0057","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1200\/JCO.2018.78.7697","article-title":"First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody\u2013drug conjugate targeting c-Met, in patients with advanced solid tumors","volume":"36","author":"Strickler","year":"2018","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.slasd.2026.100320_bib0058","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","article-title":"Phase I\/II trial of labetuzumab govitecan (Anti-CEACAM5\/SN-38 Antibody-Drug Conjugate) in patients with refractory or relapsing metastatic colorectal cancer","volume":"35","author":"Dotan","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.slasd.2026.100320_bib0059","doi-asserted-by":"crossref","first-page":"S764","DOI":"10.1016\/j.annonc.2022.07.618","article-title":"490P Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)","volume":"33","author":"Italiano","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.slasd.2026.100320_bib0060","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","article-title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody\u2013drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study","volume":"33","author":"Gazzah","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.slasd.2026.100320_bib0061","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061744","article-title":"Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings","volume":"15","author":"Lombardi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"48","key":"10.1016\/j.slasd.2026.100320_bib0062","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.slasd.2026.100320_bib0063","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-05-1961","article-title":"Clinical significance of TROP2 expression in colorectal cancer","volume":"12","author":"Ohmachi","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.slasd.2026.100320_bib0064","article-title":"Trophoblast cell-surface antigen 2 is a biomarker and potential therapeutic target in human colon cancer","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.slasd.2026.100320_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174137","article-title":"TROP2 Represents a Negative Prognostic Factor in Colorectal Adenocarcinoma and Its Expression Is Associated with Features of Epithelial\u2013Mesenchymal Transition and Invasiveness","volume":"14","author":"\u0160vec","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.slasd.2026.100320_bib0066","first-page":"1391","article-title":"Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs\u2019 development","volume":"128","author":"Moretto","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.slasd.2026.100320_bib0067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835919897543","article-title":"TROP2 overexpression in colorectal liver oligometastases is associated with poor prognosis after liver resection","volume":"11","author":"Peng","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"10.1016\/j.slasd.2026.100320_bib0068","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00384-009-0725-z","article-title":"Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer","volume":"24","author":"Fang","year":"2009","journal-title":"Int J Colorectal Dis"},{"issue":"15","key":"10.1016\/j.slasd.2026.100320_bib0069","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final Results from the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10411","key":"10.1016\/j.slasd.2026.100320_bib0070","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.slasd.2026.100320_bib0071","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.slasd.2026.100320_bib0072","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10637-024-01430-6","article-title":"A multicenter phase Ia study of AbGn-107, a novel antibody\u2013drug conjugate, in patients with advanced gastrointestinal cancer","volume":"42","author":"Ko","year":"2024","journal-title":"Invest New Drugs"},{"issue":"16_suppl","key":"10.1016\/j.slasd.2026.100320_bib0073","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.3588","article-title":"HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target","volume":"40","author":"Bent","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.slasd.2026.100320_bib0074","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/0284186X.2014.983654","article-title":"HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver","volume":"54","author":"L\u00e9del","year":"2015","journal-title":"Acta Oncol (Madr)"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-023-01692-8","article-title":"HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target","volume":"9","author":"Capone","year":"2023","journal-title":"Cell Death Discov"},{"issue":"3","key":"10.1016\/j.slasd.2026.100320_bib0076","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ejca.2013.11.008","article-title":"HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome","volume":"50","author":"L\u00e9del","year":"2014","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.slasd.2026.100320_bib0077","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/modpathol.2010.83","article-title":"Clinicopathological significance of prolactin receptor expression in colorectal carcinoma and corresponding metastases","volume":"23","author":"Harbaum","year":"2010","journal-title":"Mod Pathol"},{"issue":"January","key":"10.1016\/j.slasd.2026.100320_bib0078","first-page":"1","article-title":"Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies","volume":"13","author":"Standing","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0079","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00384-002-0414-7","article-title":"Expression of functional prolactin and its receptor in human colorectal cancer","volume":"18","author":"Otte","year":"2003","journal-title":"Int J Colorectal Dis"},{"issue":"6","key":"10.1016\/j.slasd.2026.100320_bib0080","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s10637-020-00960-z","article-title":"A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors","volume":"38","author":"Lemech","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.slasd.2026.100320_bib0081","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.12130","article-title":"RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis","author":"Bond","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.slasd.2026.100320_bib0082","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-CT167","article-title":"Abstract CT167: First-in-human clinical trial of SC-006, a RNF43 targeted antibody-drug conjugate, as a monotherapy and in combination with budigalimab in patients with advanced colorectal cancer","author":"Pedersen","year":"2020","journal-title":"Cancer Res"},{"issue":"43","key":"10.1016\/j.slasd.2026.100320_bib0083","first-page":"1","article-title":"Update on Emerging Therapies for Advanced Colorectal Cancer","author":"Alese","year":"2023","journal-title":"Am Soc Clin Oncol Educ B"},{"issue":"4","key":"10.1016\/j.slasd.2026.100320_bib0084","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3390\/vaccines10040499","article-title":"EGFR-Based Targeted Therapy for Colorectal Cancer\u2014Promises and Challenges","volume":"10","author":"Janani","year":"2022","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.slasd.2026.100320_bib0085","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jamaoncol.2022.0503","article-title":"Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial","volume":"8","author":"Qiu","year":"2022","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.slasd.2026.100320_bib0086","doi-asserted-by":"crossref","first-page":"38841","DOI":"10.18632\/oncotarget.16406","article-title":"Expression of guanylyl cyclase C in tissue samples and the circulation of rectal cancer patients","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.slasd.2026.100320_bib0087","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0189953","article-title":"Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers","volume":"12","author":"Danaee","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.slasd.2026.100320_bib0088","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00280-023-04507-w","article-title":"A phase I, first-in-human study of TAK-164, an antibody\u2013drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C","volume":"91","author":"Kim","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.slasd.2026.100320_bib0089","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-2474","article-title":"Phase I study of the investigational anti-guanylyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies","author":"Almhanna","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.slasd.2026.100320_bib0090","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat Med"},{"issue":"July","key":"10.1016\/j.slasd.2026.100320_bib0091","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.slasd.2026.100320_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.slasd.2026.100320_bib0093","article-title":"BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study","volume":"41","author":"Zhang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.slasd.2026.100320_bib0094","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor\u2013Mutated Non\u2013Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.slasd.2026.100320_bib0095","article-title":"Antibody\u2013drug conjugates: Recent advances in payloads","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"10371","key":"10.1016\/j.slasd.2026.100320_bib0096","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.slasd.2026.100320_bib0097","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","article-title":"Trastuzumab deruxtecan (DS-8201a)in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","volume":"20","author":"Shitara","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.slasd.2026.100320_bib0098","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.slasd.2026.100320_bib0099","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.slasd.2026.100320_bib0100","article-title":"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non\u2013Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study","author":"Ahn","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.slasd.2026.100320_bib0101","first-page":"1","article-title":"Tissue Cadherin 17 (CDH17): An Important Prognostic Determinant of Colorectal Cancer Using Digital Image Analysis","volume":"7","author":"Ng","year":"2024","journal-title":"Cancer Rep"},{"key":"10.1016\/j.slasd.2026.100320_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155175","article-title":"Cadherin-17 (CDH17) expression in human cancer: A tissue microarray study on 18,131 tumors","volume":"256","author":"Jacobsen","year":"2024","journal-title":"Pathol Res Pract"},{"issue":"20","key":"10.1016\/j.slasd.2026.100320_bib0103","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26209838","article-title":"The Role of Cadherin 17 (CDH17) in Cancer Progression via Wnt\/\u03b2-Catenin Signalling Pathway: A Systematic Review and Meta-Analysis","volume":"26","author":"Tha Shrestha","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"6_Supplement","key":"10.1016\/j.slasd.2026.100320_bib0104","article-title":"Abstract 1900: TORL-3-600, a novel antibody drug conjugate directed against cadherin 17 (CDH17), has preclinical efficacy in colorectal, gastric, and pancreatic cancer","volume":"84","author":"O\u2019Brien","year":"2024","journal-title":"Cancer Res"},{"issue":"8_Supplement_1","key":"10.1016\/j.slasd.2026.100320_bib0105","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-317","article-title":"Abstract 317: Discovery of HDM2017, a CDH17-targeting ADC for colorectal cancers","volume":"85","author":"Lin","year":"2025","journal-title":"Cancer Res"},{"issue":"8_Supplement_1","key":"10.1016\/j.slasd.2026.100320_bib0106","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-5469","article-title":"Abstract 5469: Preclinical safety and efficacy of SOT109, an antibody-drug conjugate targeting cadherin 17 (CDH17) for the treatment of colorectal and other gastrointestinal tract tumors","volume":"85","author":"Kalynovska","year":"2025","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.slasd.2026.100320_bib0107","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"Egfr in cancer: Signaling mechanisms, drugs and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3_suppl","key":"10.1016\/j.slasd.2026.100320_bib0108","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.135","article-title":"Amivantamab monotherapy in relapsed\/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b\/2 study","volume":"42","author":"Oberstein","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.slasd.2026.100320_bib0109","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.1016\/j.annonc.2024.08.582","article-title":"513MO Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib\/II study","volume":"35","author":"Pietrantonio","year":"2024","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"10.1016\/j.slasd.2026.100320_bib0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.197","article-title":"Amivantamab with or without chemotherapy in right-sided metastatic colorectal cancer: Updated results from OrigAMI-1, an open-label, phase 1b\/2 study","volume":"43","author":"Raghav","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.slasd.2026.100320_bib0111","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-02187","article-title":"Amivantamab Monotherapy in Chemorefractory RAS \/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib\/II Study","author":"Oberstein","year":"2026","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.slasd.2026.100320_bib0112","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/2159-8290.CD-22-1368","article-title":"Antibody\u2013Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer","volume":"13","author":"Weng","year":"2023","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.slasd.2026.100320_bib0113","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.slasd.2026.100320_bib0114","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.slasd.2026.100320_bib0115","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/bjh.14820","article-title":"Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"182","author":"Dang","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.slasd.2026.100320_bib0116","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/cas.14898","article-title":"Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models","volume":"112","author":"Furuuchi","year":"2021","journal-title":"Cancer Sci"},{"issue":"8","key":"10.1016\/j.slasd.2026.100320_bib0117","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.drudis.2021.06.012","article-title":"Duocarmycin-based antibody\u2013drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress","volume":"26","author":"Yao","year":"2021","journal-title":"Drug Discov Today"},{"issue":"11","key":"10.1016\/j.slasd.2026.100320_bib0118","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2000.18.11.2282","article-title":"Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors","volume":"18","author":"Saleh","year":"2000","journal-title":"J Clin Oncol"},{"issue":"xx","key":"10.1016\/j.slasd.2026.100320_bib0119","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ddtec.2018.08.005","article-title":"Amanitins and their development as a payload for antibody-drug conjugates","volume":"30","author":"Pahl","year":"2018","journal-title":"Drug Discov Today Technol"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.slasd.2026.100320_bib0121","unstructured":"Li Y, Li L, Fu H, Yao Q, Wang L, Lou L. Combined Inhibition of PARP and ATR Synergistically Potentiates the Antitumor Activity of HER2-Targeting Antibody-Drug Conjugate in HER2-Positive Cancers. Vol 13.; 2023. www.ajcr.us\/."},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0122","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab003","article-title":"Top1-PARP1 association and beyond: from DNA topology to break repair","volume":"3","author":"Chowdhuri","year":"2021","journal-title":"NAR Cancer"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0123","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1038\/s41467-022-31801-7","article-title":"TDP1-independent pathways in the process and repair of TOP1-induced DNA damage","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"issue":"7_Supplement","key":"10.1016\/j.slasd.2026.100320_bib0124","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2026-4436","article-title":"Abstract 4436: Sutro\u2019s site-specific dual-payload ADCs combining TOPO1i and DNA damage response inhibitors to enhance efficacy, overcome resistance, and improve safety","volume":"86","author":"Bajjuri","year":"2026","journal-title":"Cancer Res"},{"issue":"8_Supplement_1","key":"10.1016\/j.slasd.2026.100320_bib0125","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-2870","article-title":"Abstract 2870: Enhancing Topo1i ADC efficacy: development of homogeneous dual-payload ADCs combining Topo1i with microtubule inhibitors or PARP inhibitors","volume":"85","author":"Yin","year":"2025","journal-title":"Cancer Res"},{"issue":"10_Supplement","key":"10.1016\/j.slasd.2026.100320_bib0126","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-25-A124","article-title":"Abstract A124: CBB-120: A TROP2-targeted dual-payload ADC combining Top1i and ATRi mechanisms demonstrates superior efficacy in preclinical models and improved safety in non-human primates","volume":"24","author":"Anami","year":"2025","journal-title":"Mol Cancer Ther"},{"issue":"15","key":"10.1016\/j.slasd.2026.100320_bib0127","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41388-023-02638-1","article-title":"Ras protein abundance correlates with Ras isoform mutation patterns in cancer","volume":"42","author":"Hood","year":"2023","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.slasd.2026.100320_bib0129","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17030428","article-title":"The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives","volume":"17","author":"Takeda","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0130","article-title":"KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials","volume":"9","author":"Navarro-Jim\u00e9nez","year":"2025","journal-title":"npj Precis Oncol"},{"issue":"23","key":"10.1016\/j.slasd.2026.100320_bib0131","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.slasd.2026.100320_bib0132","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N Engl J Med"},{"issue":"8_Supplement_1","key":"10.1016\/j.slasd.2026.100320_bib0133","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-6737","article-title":"Abstract 6737: RAS inhibitors as payloads of ADCs to treat RAS-mutant tumors","volume":"85","author":"Zhong","year":"2025","journal-title":"Cancer Res"}],"container-title":["SLAS Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555226000262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555226000262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:51:05Z","timestamp":1785909065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472555226000262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":133,"alternative-id":["S2472555226000262"],"URL":"https:\/\/doi.org\/10.1016\/j.slasd.2026.100320","relation":{},"ISSN":["2472-5552"],"issn-type":[{"value":"2472-5552","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ADCs for colorectal carcinoma: decoding clinical evidence for molecular design innovation","name":"articletitle","label":"Article Title"},{"value":"SLAS Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.slasd.2026.100320","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening.","name":"copyright","label":"Copyright"}],"article-number":"100320"}}